Idiopathic inflammatory myopathy, also known as myositis, is a rare muscle disease with no effective therapies and few experimental treatments in development. But a new research initiative by NCATS scientists could point to promising new options. They swiftly tested thousands of existing drugs to find therapeutics that may target a key trigger in myositis.
Myositis is an autoimmune disease characterized by chronic inflammation of the muscles. A person’s own immune system attacks their muscle cells, leading to skeletal muscle weakness and pain, as well as complications in the skin, lungs and circulatory system.